Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

BACKGROUND: Overall survival (OS) is the gold standard to assess novel therapeutics to treat cancer. However, to identify early efficacy and speed up drug approval, trials have used progression-free survival (PFS) as a surrogate endpoint (SE). Herein, we aimed to examine if PFS could function as an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zewei, Xie, Chunxia, Gao, Tiantian, Yang, Yuxian, Yang, Yong, Zhao, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921746/
https://www.ncbi.nlm.nih.gov/pubmed/36765311
http://dx.doi.org/10.1186/s12885-023-10613-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921746/
https://www.ncbi.nlm.nih.gov/pubmed/36765311
http://dx.doi.org/10.1186/s12885-023-10613-y

Ejemplares similares